Step 1 topics → Musculoskeletal, Skin, and Connective Tissue → Melanoma

Melanoma

USMLE Step 1 trap: Confuses Clark level with Breslow thickness as the primary prognostic depth measurement in melanoma. Breslow thickness (measured in millimeters) is the primary prognostic factor for melanoma; Clark level has largely been replaced by Breslow in staging.

Melanoma is the deadliest skin cancer, and USMLE Step 1 tests it hard — not just identification, but staging logic, biopsy decisions, molecular targets, and subtype-specific behavior. The core concept is that melanoma arises from melanocytes, can occur anywhere (skin, eye, mucosa, nail bed), and that prognosis hinges almost entirely on Breslow thickness — how deep the tumor has invaded in millimeters. The exam will give you a clinical vignette with ABCDE features or a subungual pigmented lesion and ask about next steps, prognostic factors, or appropriate biopsy technique.

The tricky parts are where students conflate similar-sounding concepts. Clark level (I–V, based on anatomic skin layer) sounds authoritative but has largely been replaced by Breslow thickness in modern staging — Step 1 will specifically test whether you know this distinction. Biopsy technique is another high-yield trap: shave biopsy is the wrong answer for suspected melanoma because it cuts through the lesion and destroys your ability to measure Breslow depth accurately. The exam also tests molecular biology — BRAF V600E is the driver mutation in superficial spreading and nodular melanoma, but acral lentiginous and mucosal subtypes lean on KIT mutations, not BRAF.

Subtype ranking is frequently tested and frequently confused. There are four main subtypes — superficial spreading (most common), lentigo maligna (sun-damaged skin in elderly), acral lentiginous (palms/soles/nails, not UV-driven), and nodular (worst prognosis, vertical growth from day one). Understanding why nodular melanoma has the worst outcomes — not rarity, but its immediate vertical growth phase bypassing the radial phase — is the kind of mechanism-level reasoning USMLE Step 1 rewards.

From real student decks
78%have cards covering this topic
54%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Clark level (anatomic layer) is the primary prognostic measure for melanoma depth.
Right: Breslow thickness (measured in millimeters) is the primary prognostic factor for melanoma; Clark level has largely been replaced by Breslow in staging.
Clark level classifies invasion by anatomic skin layer (epidermis through subcutaneous fat, levels I–V), which sounds like a precise prognostic tool — but it's subjective and poorly reproducible. Breslow thickness is a direct millimeter measurement from the granular layer of the epidermis to the deepest tumor cell, making it objective and reproducible. Modern AJCC staging uses Breslow thickness as the primary depth determinant; Clark level only appears as a minor modifier in thin lesions (T1). If the exam asks which depth measure drives prognosis, the answer is Breslow — always.
Common mistake
Wrong: A shave biopsy is appropriate for a suspected melanoma.
Right: Suspected melanoma requires excisional biopsy with narrow margins to preserve full Breslow depth measurement; shave biopsy is contraindicated.
A shave biopsy cuts parallel to the skin surface at a shallow depth, which risks transecting the deepest part of the tumor. Since Breslow thickness is measured from the granular layer down to the deepest tumor cell, an incomplete biopsy artificially truncates that measurement — you lose the ability to accurately stage the lesion and plan surgery. Excisional biopsy with 1–3 mm margins removes the entire lesion intact, preserving the full depth for pathologic measurement. Punch biopsy through the thickest part of the lesion is acceptable if excision isn't feasible, but shave biopsy is never appropriate for a suspected melanoma.
Common mistake
Wrong: BRAF V600E mutations are found in all melanoma subtypes equally.
Right: BRAF V600E is most common in superficial spreading and nodular melanoma arising on intermittently sun-exposed skin; acral lentiginous and mucosal melanomas more often harbor KIT mutations.
BRAF V600E arises in melanocytes exposed to intermittent UV radiation — the kind that causes sunburns on back or legs — which is why it's enriched in superficial spreading and nodular melanoma. Acral lentiginous melanoma (palms, soles, subungual) and mucosal melanoma occur in UV-protected sites, so their pathogenesis is UV-independent and instead driven by KIT amplifications and mutations. This matters clinically: vemurafenib and dabrafenib only work if BRAF V600E is present, so acral and mucosal subtypes typically don't respond to these agents and require different targeted approaches (imatinib for KIT-mutant disease).
Common mistake
Wrong: Nodular melanoma has a better prognosis than superficial spreading melanoma because it is less common.
Right: Nodular melanoma has the worst prognosis among common subtypes because it grows vertically from the outset, achieving greater Breslow depth rapidly.
The intuition that 'less common = less dangerous' doesn't apply here. Nodular melanoma skips the radial (horizontal) growth phase that other subtypes go through, and immediately enters vertical growth — invading downward into the dermis from the outset. Because Breslow depth is the primary driver of prognosis and sentinel node positivity, nodular melanoma reaches dangerous depths faster than any other subtype, leading to worse outcomes at the time of diagnosis. Superficial spreading melanoma, despite being the most common, often has a prolonged radial phase where it remains thin and curable.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolution) and the 'ugly duckling' concept — a lesion that looks different from a patient's other nevi should raise suspicion regardless of whether it meets all ABCDE criteria.
  2. Distinguish melanoma subtypes by location, patient population, and prognosis: superficial spreading is most common, nodular has the worst prognosis due to early vertical invasion, lentigo maligna occurs on chronically sun-damaged skin in older patients, and acral lentiginous appears on palms/soles/nail beds and is not UV-associated.
  3. Identify Breslow thickness as the primary prognostic factor for melanoma depth — not Clark level — and recognize that excisional biopsy with narrow margins is required to preserve an accurate Breslow measurement; shave biopsy is contraindicated.
  4. Know the molecular drivers of melanoma: BRAF V600E is the dominant mutation in superficial spreading and nodular subtypes (treated with vemurafenib/dabrafenib), while acral lentiginous and mucosal melanomas more commonly carry KIT mutations; also know checkpoint inhibitors ipilimumab (anti-CTLA-4) and nivolumab/pembrolizumab (anti-PD-1) for advanced disease.
  5. Apply the surgical management algorithm: wide local excision margins are determined by Breslow depth, sentinel lymph node biopsy is indicated for lesions ≥0.8 mm or with high-risk features, and systemic therapy is used for metastatic or unresectable disease.

Can you avoid these mistakes?

A 55-year-old man has a 1.2 cm pigmented lesion on his back with irregular borders and three different shades of brown. Dermatology wants to biopsy it. Which biopsy technique is contraindicated, and why?
A pathology report describes a melanoma with Breslow thickness of 2.1 mm and Clark level IV. Which measurement determines the T-stage in current AJCC staging, and what does this mean for surgical margin width and sentinel node biopsy eligibility?
A 65-year-old woman with no significant sun exposure has a new pigmented streak under her thumbnail. Biopsy confirms melanoma. Which molecular mutation is more likely to be driving this tumor — BRAF V600E or a KIT mutation — and how does this affect targeted therapy selection?
Rank these melanoma subtypes from best to worst prognosis and explain the biological reason nodular melanoma ranks where it does: superficial spreading, nodular, lentigo maligna, acral lentiginous.

Related topics

Bone Cells and Matrix Endochondral vs Membranous Ossification Fracture Healing Stages Compartment Syndrome

See how your Anki deck covers this topic.

Upload your deck for a free audit →